SCHEMBL4365533

SCHEMBL4365533

O=C(NSc1cccc(Oc2ccccn2)c1)NC(=O)c1cc2ccccc2o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 11/20 0.47
RAB9A P51151 10/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
TP53 P04637 4/20 0.47
PKM P14618 2/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 2/20 0.45
HSP90AA1 P07900 1/20 0.45
HTT P42858 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TSHR P16473 4/20 0.42
HPGD P15428 2/20 0.42
LMNA P02545 2/20 0.40
ALDH1A1 P00352 3/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4360383 0.87 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL4375566 0.82 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL4361546 0.82 HPGD (0.49) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL4369761 0.79 BCAT1 (0.46) NPC1RAB9ASMN1; SMN2TP53MEN1
SCHEMBL4538068 0.79 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL2862481 0.79 PTPN22 (0.39) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL4365541 0.78 ALDH1A1 (0.61) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL4361498 0.77 FFAR1 (0.41) SMN1; SMN2MEN1KMT2AKDM4EL3MBTL1
SCHEMBL4543532 0.77 RAB9A (0.45) NPC1RAB9ASMN1; SMN2MAPTTDP1
SCHEMBL4366834 0.77 DRD3 (0.38) NPC1RAB9ASMN1; SMN2TP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US claimed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US claimed
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2004-07-15 US claimed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, TPMT NPC1 107/4885RAB9A 2176/4885SMN1; SMN2 2545/4885
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 NPC1 151/4885RAB9A 2273/4885SMN1; SMN2 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.